Vietnam In-Vitro Diagnostics Market By Product & Service (Reagents, Instruments, Software & Services), By Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, Others), By Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

Vietnam In-Vitro Diagnostics Market was valued at USD 336.07 Million in 2024 and is expected to reach USD 441.23 Million by 2030 with a CAGR of 4.60% during the forecast period.

The In-vitro Diagnostics (IVD) market in Vietnam is witnessing significant growth, fueled by various factors reflecting the country's healthcare advancements and the evolving needs of its population. This market includes a broad spectrum of diagnostic tests conducted on biological samples such as blood, urine, and tissues, aimed at detecting diseases, conditions, and infections.

The rising incidence of chronic diseases like diabetes, cardiovascular diseases, and cancer in Vietnam has heightened the demand for early and accurate diagnostic solutions. The Vietnam IVD market is set for robust expansion, supported by favorable demographic trends, government initiatives, and technological innovations. However, addressing regulatory, economic, and educational challenges will be essential for sustaining this growth and ensuring widespread access to advanced diagnostic solutions. Companies in this market must navigate these complexities while continuing to innovate and adapt to the evolving healthcare landscape in Vietnam.

Key Market Drivers

Epidemiological Shifts and Rising Chronic Disease Burden

Vietnam is experiencing a significant rise in chronic diseases, driving strong demand for In-vitro Diagnostics (IVD). Conditions like diabetes, cardiovascular diseases, and cancer are increasing due to aging, urbanization, and lifestyle changes. Diabetes incidence is growing rapidly, requiring continuous blood glucose monitoring, which depends on IVD tools. Regular diagnostic testing supports disease management, treatment adjustments, and complication prevention. Cardiovascular diseases, a leading cause of death, demand extensive testing for early detection, risk assessment, and monitoring treatment efficacy. Rising hypertension and heart disease rates increase the use of tests such as lipid profiles, cardiac biomarkers, and coagulation panels. Increasing cancer cases emphasize the need for precise, early diagnosis to guide effective treatment.

Vietnam is among the top 10 countries with a high tuberculosis burden, with over 170,000 annual diagnoses, yet fewer than 60% receive adequate treatment. Government data show a >400% increase in confirmed TB cases in 2022 versus 2021, totaling over 360,000 cases with around 140 deaths. Combined with rising chronic disease prevalence, this intensifies demand for IVD, as healthcare systems work to improve diagnostic and treatment outcomes. Advanced techniques like molecular diagnostics and tissue biopsies are critical for cancer detection, understanding progression, and enabling personalized treatment.

Demographic trends show a rapidly aging population prone to diabetes, hypertension, and cancer, all requiring ongoing diagnostics. In 2019, 11.9% of the population was aged 60+, expected to exceed 25% by 2050. Government initiatives, such as the National Strategy to End the AIDS Epidemic by 2030, and frequent health screenings among the elderly, boost IVD demand. Urbanization and lifestyle changes also raise chronic disease risk through reduced physical activity, poor diet, stress, obesity, and related disorders, further increasing diagnostic test utilization. Occupational health risks in urban settings also contribute.

Public awareness programs, free or subsidized screening initiatives, and mass screenings for diseases like diabetes, cancer, and hepatitis B and C drive market growth. Health campaigns have improved health-seeking behavior, with more individuals undergoing regular check-ups and testing. Advances in diagnostics, including portable devices, point-of-care testing, and molecular diagnostics, allow faster, more accurate, and less invasive testing. These developments support continuous monitoring, early intervention, and personalized treatment, enhancing chronic disease management and expanding Vietnam’s IVD market..

Government Initiatives and Healthcare Infrastructure Development

In recent years, Vietnam has significantly increased healthcare spending to improve public health outcomes. According to the Economist Intelligence Unit, healthcare expenditure reached about USD 18.5 billion in 2022, or 4.6% of GDP. This funding has driven key developments that benefit the in-vitro diagnostics (IVD) market.

Additional resources have modernized and expanded hospitals and clinics, enabling integration of advanced IVD technologies and improving diagnostic capabilities. Healthcare institutions can acquire cutting-edge diagnostic equipment, increasing accuracy and the range of available tests. National programs focused on early disease detection and prevention have further boosted demand for IVD testing.

Regulatory reforms have streamlined approval processes for medical devices, including IVD products, reducing time and cost to market. These reforms, aligned with international standards, facilitate entry of high-quality diagnostics, enhancing patient outcomes. Vietnam is also upgrading healthcare infrastructure to reduce medical tourism abroad.

From March 2024, six hospitals in Hanoi, Ho Chi Minh City, and Thừa Thiên-Huế will be modernized to international standards, equipped with advanced technologies, and provide world-class services. By 2025, targets include 33 hospital beds, 15 doctors, 3.4 pharmacists, and 25 nurses per 10,000 people. By 2050, Vietnam aims to establish modern, internationally accredited facilities and expand private healthcare, supported by government incentives like tax breaks and subsidies for diagnostic centers.

These initiatives are establishing facilities with the latest IVD technologies. Efforts to expand healthcare access in rural areas, including building clinics and deploying mobile health units, are increasing demand for portable, easy-to-use IVD devices. Government support for telemedicine and remote diagnostics is also growing, with IVD playing a critical role by enabling remote analysis by specialists.

Technological Advancements and Innovation

Technological advancements in in-vitro diagnostics (IVD) have greatly improved test accuracy and efficiency, driving market growth in Vietnam. Molecular diagnostics, including PCR and next-generation sequencing, enable precise detection of genetic mutations, pathogens, and biomarkers, supporting definitive diagnoses, better patient management, and personalized treatment. Advances in immunoassays, such as chemiluminescent and fluorescent assays, enhance sensitivity and specificity, enabling early detection and monitoring of chronic and infectious diseases.

Point-of-care testing (POCT) devices have transformed the IVD market by providing rapid results at the site of care. Immediate diagnostics accelerate clinical decisions, improving patient outcomes, particularly in emergency and critical care. Portable, easy-to-use POCT devices increase access to diagnostics in rural and remote areas, supporting underserved populations.

Automation and AI integration are streamlining laboratory workflows, reducing errors, and increasing throughput. High-volume automated systems meet growing demand, while AI and machine learning analyze complex data, detect patterns, and improve test reliability. Technological advances in sample collection and processing, including non-invasive and minimally invasive methods like saliva tests and micro-sampling, enhance patient comfort and encourage frequent testing, which is essential for chronic disease management and population screening. Innovations in sample preservation and transport maintain sample integrity, ensuring accurate results.

Digital health integration further strengthens IVD’s impact. Telemedicine and remote monitoring allow patients to use home-based diagnostic kits and share results digitally with healthcare providers. This facilitates continuous monitoring of chronic conditions. Linking IVD results with electronic health records enables comprehensive patient data management, allowing clinicians to make informed decisions based on complete medical histories. These innovations collectively improve diagnostic accessibility, accuracy, and patient care, driving the expansion of Vietnam’s IVD market.

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles and Compliance Issues

The regulatory landscape for medical devices, including IVD products, in Vietnam can be complex and stringent, posing significant challenges for market entry and expansion. The approval process for new diagnostic products is often lengthy and involves multiple bureaucratic layers. This can delay the introduction of innovative diagnostic technologies into the market, limiting the availability of advanced diagnostic tools. Ensuring compliance with local regulatory standards, which may differ from international norms, can be challenging for multinational companies. This often requires additional adjustments to products and documentation, increasing time and costs. The regulatory environment in Vietnam is evolving, with frequent updates and changes. Keeping up with these changes requires continuous monitoring and adaptability, which can be resource-intensive for companies.

Economic Disparities and Limited Healthcare Access

Economic disparities and limited healthcare access, particularly in rural and underserved areas, present significant barriers to the widespread adoption of IVD technologies. Significant income disparities exist between urban and rural populations. High costs of advanced diagnostic tests may not be affordable for a large segment of the population, restricting the market reach of IVD products. Rural areas often lack the necessary healthcare infrastructure, including diagnostic laboratories and trained personnel, to effectively utilize advanced IVD technologies. This limits the penetration of IVD services outside major urban centers. Although healthcare insurance is expanding, coverage for diagnostic tests remains limited. Out-of-pocket expenses for diagnostic services can be prohibitively high for many patients, reducing the demand for these services.

Shortage of Skilled Healthcare Professionals

The effective utilization of advanced IVD technologies requires a skilled workforce, which is currently in short supply in Vietnam. There is a shortage of healthcare professionals trained in the latest diagnostic technologies. This gap affects the quality and reliability of diagnostic services, as well as the ability to fully leverage advanced IVD tools. Rapid technological advancements in the IVD sector necessitate continuous education and training for healthcare providers. The current educational infrastructure is often inadequate to keep pace with these needs, resulting in a skills gap. Retaining skilled professionals is challenging due to better opportunities and compensation packages in other countries. This brain drain further exacerbates the shortage of qualified personnel in Vietnam's healthcare sector.

Key Market Trends

Adoption of Personalized Medicine and Precision Diagnostics

The shift towards personalized medicine is a critical trend that will significantly drive the growth of the IVD market in Vietnam. Advances in genomic testing and molecular diagnostics are enabling more precise identification of genetic mutations and biomarkers associated with various diseases. This trend supports the development of targeted therapies, enhancing treatment efficacy and patient outcomes. As the Vietnamese healthcare system adopts these technologies, the demand for sophisticated IVD tests will increase.

Personalized medicine involves tailoring treatment plans to individual patients based on their genetic profile and specific disease characteristics. This approach relies heavily on accurate and comprehensive diagnostic information provided by advanced IVD tests. As healthcare providers in Vietnam increasingly move towards personalized treatment strategies, the utilization of IVD technologies will expand. Personalized medicine is particularly beneficial for managing chronic diseases such as cancer, diabetes, and cardiovascular diseases. By using IVD tests to monitor disease progression and treatment response, healthcare providers can make more informed decisions, leading to better patient management and outcomes. This will drive continuous demand for IVD solutions.

Integration of Digital Health and Telemedicine

The integration of digital health technologies and telemedicine is transforming healthcare delivery in Vietnam, creating new opportunities for the IVD market. Telemedicine and remote healthcare, accelerated by COVID-19, have increased demand for remote diagnostic capabilities. Home-based diagnostic kits and portable IVD devices allow patients to perform tests at home and share results with providers, driving demand for user-friendly, reliable solutions.

Digital health platforms increasingly use AI and data analytics to improve diagnostic accuracy and efficiency. AI algorithms analyze large datasets from IVD tests, identify patterns, and provide actionable insights, enhancing outcomes and streamlining clinical workflows. This integration of AI in diagnostics strengthens the value of IVD solutions and supports market growth.

Over 92% of public hospitals have partnered with local IT firms such as FPT, Link Toan Cau, Dang Quang, and OneNET to implement digital health solutions. Private facilities, including Hoan My and Vinmec, have upgraded digital infrastructure to manage expanding networks, while foreign-invested hospitals are investing in platforms to enhance service delivery and operational efficiency.

The integration of digital health fosters innovation, expands diagnostic services, and improves interoperability. Connected systems ensure IVD test data is accessible to providers, enhancing efficiency and care quality. This trend toward interoperable healthcare platforms supports widespread adoption of IVD technologies, boosting demand for digital diagnostic solutions across Vietnam.

Expansion of Point-of-Care Testing (POCT) and Decentralized Diagnostics

The expansion of point-of-care testing (POCT) and decentralized diagnostic solutions is a significant trend driving the growth of the IVD market in Vietnam. POCT devices provide rapid and accurate diagnostic results at the site of patient care, such as clinics, community health centers, and even at home. This accessibility is particularly important in Vietnam, where rural and underserved areas may lack advanced laboratory facilities. The convenience and immediacy of POCT are driving their adoption across various healthcare settings.

POCT devices are crucial for the ongoing monitoring of chronic diseases, allowing for regular and immediate assessment of conditions such as diabetes and cardiovascular diseases. This continuous monitoring helps in timely intervention and better disease management, thus increasing the reliance on POCT solutions. Advances in POCT technologies, including miniaturization, enhanced sensitivity, and integration with mobile health platforms, are making these devices more effective and user-friendly. Innovations such as multiplexing capabilities, which allow multiple tests to be conducted simultaneously on a single device, are expanding the range of applications for POCT. This technological progress will continue to drive the growth of the IVD market by making diagnostic testing more versatile and accessible.

Segmental Insights

Technique Insights

Based on Technique, the Immunodiagnostics emerged as the fastest growing segment in the Vietnam In-Vitro Diagnostics market during the forecast period. Immunodiagnostic tests, such as enzyme-linked immunosorbent assays (ELISAs) and rapid immunochromatographic assays, are extensively used for screening and diagnosing conditions like hepatitis B and C, as well as HIV. The high prevalence of these diseases ensures sustained demand for immunodiagnostic testing. Additionally, the rise of emerging infectious diseases, including zoonotic infections and tropical diseases, further drives the need for these tests, which are critical for early detection and effective outbreak management, thus supporting public health efforts.

According to the World Health Organization (WHO), Vietnam ranks 5th in life expectancy for men and 2nd for women among 10 Southeast Asian countries. On average, the Vietnamese population has a life expectancy of 73.7 years, although they live with chronic illness for approximately 10 years. This increasing incidence of chronic conditions such as diabetes, cardiovascular diseases, and cancer in Vietnam is another key factor fueling the growth of the immunodiagnostics segment.

Immunodiagnostic tests are vital for detecting cardiac biomarkers, such as troponins and BNP, which aid in diagnosing and managing heart diseases. The rising prevalence of cardiovascular conditions further amplifies the demand for these tests. In oncology, immunodiagnostic tests are essential for detecting specific tumor markers (e.g., PSA for prostate cancer, CA-125 for ovarian cancer), enabling early detection and monitoring of cancer, which is critical for improving patient outcomes. Continuous advancements in immunodiagnostic technologies are enhancing test sensitivity, specificity, and overall diagnostic accuracy, making them more reliable and appealing for broader use.

Innovations such as chemiluminescent immunoassays (CLIAs) and time-resolved fluorescence immunoassays (TRFIAs) offer improved sensitivity and specificity, essential for accurate diagnosis and monitoring. The development of multiplex immunoassays, which allow the simultaneous detection of multiple analytes from a single sample, enhances efficiency and reduces costs, making them particularly valuable for large-scale screening programs.

Application Insights

Based on application, Infectious Diseases emerged as the dominating segment in the Vietnam In-Vitro Diagnostics market in 2024. Vietnam continues to face a significant public health challenge due to the widespread presence of infectious diseases such as hepatitis B and C, HIV, and tuberculosis. These conditions create a persistent demand for diagnostic testing. Hepatitis B and C are especially concerning, while HIV remains a key focus for screening and early intervention initiatives.

Additionally, the emergence of new infectious threats, including zoonotic and tropical diseases, has increased the need for fast and accurate diagnostic solutions. Outbreaks of diseases like dengue and influenza require constant monitoring, early identification, and rapid response, all of which rely on effective diagnostic tools.  In response, the Vietnamese government has rolled out various public health programs aimed at controlling and preventing the spread of these infectious diseases.

National screening campaigns and efforts to curb transmission, particularly for HIV and hepatitis, have driven up the use of IVD tests. Early detection is essential for controlling and halting the spread of these diseases, and immunodiagnostic tests, such as enzyme-linked immunosorbent assays (ELISAs) and rapid immunochromatographic assays, are crucial for this purpose.

As these tests gain wider usage through government health initiatives, they play a major role in boosting demand for IVD products across the country. The ongoing prevalence of infectious diseases, supported by proactive public health programs and the increasing need for reliable, rapid diagnostics, positions this segment as the primary driver of the IVD market in Vietnam.

Download Free Sample Report

Regional Insights

Based on Region, Southern Vietnam emerged as the dominating region in the Vietnam In-Vitro Diagnostics market in 2024. South Vietnam, particularly major cities like Ho Chi Minh City (formerly Saigon), functions as the country's economic and financial nucleus. This region possesses sophisticated healthcare infrastructure, comprising contemporary hospitals, clinics, and diagnostic laboratories equipped with state-of-the-art IVD technologies.

The concentration of healthcare facilities in South Vietnam facilitates widespread access to diagnostic services for a substantial portion of the population. South Vietnam exhibits a higher population density compared to other regions, characterized by both urban and suburban areas. This dense demographic creates a sizable market for healthcare services, including diagnostic testing. Additionally, South Vietnam attracts skilled healthcare professionals, encompassing doctors, laboratory technicians, and researchers, who actively contribute to the advancement and application of advanced IVD technologies within the region.

The southern region of Vietnam, particularly urban centers like Ho Chi Minh City, stands at the forefront of technological advancements and innovation within the healthcare sector. The presence of eminent research institutions, medical universities, and biotechnology companies cultivates an environment conducive to innovation, driving the development of pioneering diagnostic solutions. South Vietnam thus serves as a focal point for research and development endeavors related to IVD technologies, facilitating the introduction of cutting-edge diagnostic products into the market.

Recent Developments

• In September 2024, Roche Pharma Vietnam celebrated its 30th anniversary, with representatives from the Ministry of Health, Roche Pharma Vietnam, and Silvia Barceleiro, head of Egypt, Morocco, Vietnam, and Indonesia for Roche Pharma International, in attendance. Roche’s Patient Support Programs have benefited over 1,500 individuals, with an estimated value exceeding VND 290 billion (USD 11.78 million). Beyond its established strengths in oncology and hematology, Roche plans to introduce cutting-edge ophthalmology technologies later this year to address the increasing challenges in this area in Vietnam.
• In May 2024, Japan's Hitachi High-Tech and Swiss company Roche renewed their partnership, agreeing to extend their collaboration for a minimum of 10 more years. Later this year, the two companies plan to launch new innovations, including the cobas c 703 and cobas ISE neo analytical units for cobas pro integrated solutions. These advancements aim to enhance testing capacity in laboratories and provide accurate, timely diagnoses for millions of patients globally.
• In July 2024, FUJIFILM Corporation announced the launch of its first "NURA" health screening center in Southeast Asia, located in Hanoi, Vietnam. The center will focus on cancer screening and is operated by VIETNAM JAPAN HEALTH TECHNOLOGY JOINT STOCK COMPANY (VJH), which also owns T-Matsuoka Medical Center in Vietnam. FUJIFILM DKH LLP, a Fujifilm subsidiary that operates NURA centers in India and Mongolia, will support VJH in providing health screenings with an emphasis on cancer and lifestyle-related diseases. This marks the beginning of Fujifilm's plan to expand its health screening services in emerging markets by increasing the number of NURA centers.
• In July 2024, GC Holdings signed a shareholders agreement (SHA) with Phenikaa Group to establish Vietnam's first comprehensive diagnostic and interpretation institution, focusing on genetics and cancer. This partnership aims to utilize GC Lab's extensive expertise to create a cutting-edge commercial laboratory in Vietnam, offering precision diagnostics. Additionally, GC i-MED, a subsidiary specializing in comprehensive health check-ups, plans to open a premium health check-up center catering to the local middle and upper classes. The center will integrate advanced diagnostic programs to ensure fast and accurate results. Using state-of-the-art medical equipment and digital solutions, the center will offer specialized services, including endoscopic examinations by Korean specialists. The facility will be located in one of the four buildings of Phenikaa Group’s new 800-bed general hospital in Hanoi's Nam Từ Liêm district, which is nearing completion and scheduled to open next month.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories GmbH
• Siemens Vietnam
• Thermo Fisher Scientific Inc
• Natera, Inc.
• Agilent Technologies, Inc
• BD Vietnam Co. Ltd.

Report Scope:

In this report, the Vietnam In-vitro Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vietnam In-vitro Diagnostics Market, By Product & Service:

o   Reagents

o   Instruments

o   Software & Services

• Vietnam In-vitro Diagnostics Market, By Technique:

o   Immunodiagnostics

o   Hematology

o   Molecular Diagnostics

o   Tissue Diagnostics

o   Clinical Chemistry

o   Others  

• Vietnam In-vitro Diagnostics Market, By Application:

o   Infectious Diseases

o   Cancer

o   Cardiac Diseases

o   Immune System Disorders

o   Nephrological Diseases

o   Others

• Vietnam In-vitro Diagnostics Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Laboratories

o   Others

• Vietnam In-vitro Diagnostics Market, By Region:

o   Southern Vietnam

o   Northern Vietnam

o   Central Vietnam

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Vietnam In-vitro Diagnostics Market.

Available Customizations:

Vietnam In-vitro Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Vietnam In-vitro Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]